Novartis Bullish About Prexige; Anticipates Blockbuster Potential
This article was originally published in The Pink Sheet Daily
Executive Summary
Company takes a more bullish stance on its COX-2 inhibitor than Merck, which has assumed FDA approval of its Vioxx follow-on product Arcoxia in 2007.
You may also be interested in...
Novartis Withdraws Prexige In Australia Ahead Of FDA Decision Due To Deaths
A decision to withdraw Novartis' Prexige (lumiracoxib) in Australia after two patients died from serious liver injury following treatment with the drug is likely to impact the outcome of FDA's decision on a pending NDA for the COX-2 inhibitor
Novartis Withdraws Prexige In Australia Ahead Of FDA Decision Due To Deaths
Withdrawal of the COX-2 inhibitor in Australia following two deaths from liver injury is likely to impact the outcome of FDA’s review.
Novartis Withdraws Prexige In Australia Ahead Of FDA Decision Due To Deaths
Withdrawal of the COX-2 inhibitor in Australia following two deaths from liver injury is likely to impact the outcome of FDA’s review.